Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
Sable Offshore (SOC) is up 20.0%, or $4.90 to $29.37.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback